On Wednesday 3rd December , we’re heading to the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s premier gatherings for groundbreaking hematology research. This year, we’re not only attending, but we’re also co-hosting our own symposium with Decera Clinical Education and holding a workshop with FLF supported investigators bringing together pioneering researchers who are pushing the boundaries of what’s possible in follicular lymphoma (FL).
What is ASH?
To The ASH Annual Meeting brings together more than 30,000 hematologists, researchers, clinicians, and industry leaders from around the world. Each year, it serves as a global hub for sharing the latest discoveries in blood cancers and blood disorders, from early laboratory science to late-stage clinical trials. For anyone working in lymphoma research, ASH is where new ideas are introduced, collaborations are sparked, and the future direction of the field takes shape.
Driving progress at ASH
Our mission is simple yet bold: to help unlock a cure for follicular lymphoma. But this isn’t something any single team or organisation can achieve alone. Around the world, exceptional researchers are advancing their own specialized areas of science, but true progress accelerates when ideas converge.
That’s why we’re bringing people together: not only to foster collaboration, but to shine a brighter light on follicular lymphoma, expand funding opportunities, and create a space for learning that pushes the field forward. Through our symposium and other key gatherings, we’re uniting the researchers dedicated specifically to FL, encouraging them to share insights, challenge assumptions, and spark the breakthroughs that happen only when the right minds are in the same room.
In the symposium experts will share advice to clinicians on how best to use new treatments like bispecific antibodies and CAR-T to help people whose FL has returned or not responded to previous treatment. Dr Mitchell Smith, FLF’s CMO, will take to the stage to ensure the patient voice is front and centre in these discussions.
Why collaboration matters for FL
Collaboration accelerates progress, especially in a rare disease like FL. When experts connect, they share insights, avoid duplication, and spark new ideas. Because many FL researchers focus on very specific areas, it can be hard for them to find peers who truly understand their work. By hosting events at conferences like ASH, we’re helping build a global network that breaks down those barriers.
And progress in the lab is only the start. A cure can only reach patients through large-scale clinical trials, which are far more challenging in rare diseases. Trials often need to span continents so they can find enough people to take part and make sure the results reflect a wide mix of patients. By strengthening international partnerships, we help lay the groundwork for future trials, and ultimately, better treatments.
Putting patients at the heart of research
Last month (November 2025) we held workshops, online and in person, with people affected by FL, asking what they want research to achieve and barriers to accessing clinical trials. We have also drawn on findings from our recent global patient survey, which highlight real-world challenges, priorities and hopes of 1000+ people living with FL. By bringing these insights to ASH and engaging directly with scientists, clinicians, and pharmaceutical leaders, we’re making sure patient voices are heard where it matters most.
Look out for updates
Throughout and after the conference the FLF team on the ground will share insights, alongside the most interesting scientific and clinical updates from the field. Look out on our website and social media channels for updates!
Support our mission
Join us in driving life-changing research for people living with follicular lymphoma. Your support directly fuels innovative science, global collaboration, and the search for a cure.
Together, we can bring a cure for follicular lymphoma within reach.
